TG Therapeutics Inc (STU:NKB2)
€ 15.004 -0.278 (-1.82%) Market Cap: 2.33 Bil Enterprise Value: 2.24 Bil PE Ratio: 74.36 PB Ratio: 15.79 GF Score: 73/100

TG Therapeutics, Inc. - Shareholder/Analyst Call Transcript

Dec 10, 2019 / 01:00AM GMT
Release Date Price: €8.13 (-4.47%)
Michael S. Weiss
TG Therapeutics, Inc. - Executive Chairman, CEO & President

Okay. So we've got a great panel. I'm Mike Weiss, I'm the CEO of TG. Thank you all for joining us.

To my right, I've got my co-moderator and Cantor biotech analyst, Alethia Young. Give it up. And then for our panel, we have the first chair, Pier Luigi Zinzani from Bologna, Italy. All the way from Bologna, Italy, gracing us. A world leader in indolent lymphomas, marginal zone, follicular, and I'm sure treats diffuse large B-cell as well.

To his right, Dr. Paul Barr, from the University of Rochester. Yes? That was University of Rochester? Double check. Paul has been involved in TG studies. He's an expert in CLL and lymphoid malignancies generally as well. And was the presenter and lead enroller of -- and really his trial, the Phase I/II for U2 plus venetoclax.

To his right, we have Javier Pinilla from the Moffitt Cancer Center. Also a leader in B-cell malignancies, CLL and other lymphoid malignancies as well, I'm sure. Javier has been a lead enroller in a lot of our clinical trials and also is a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot